Literature DB >> 35673915

[MiR-744-5p inhibits the proliferation, invasion, and migration of clear-cell renal cell carcinoma cells by targeting CCND1].

K Lei1, W Xie1, T Sun1, Y Liu1, X Wang2.   

Abstract

OBJECTIVE: To explore the role of miR-744-5p/CCND1 axis in clear-cell renal cell carcinoma (ccRCC).
METHODS: We examined the expression levels of miR-744-5p in 65 pairs of ccRCC and adjacent tissue specimens and in 5 ccRCC cell lines and human renal tubular epithelial (HK2) cells using qRT-PCR. The ccRCC cell lines 786-O and OSRC2 were transfected with miR-744-5p mimic, CCND1 mimic, or their negative control mimics, and the changes in cell proliferation, migration, and invasion were evaluated with CCK-8, wound healing, and Transwell assays. The downstream target molecules of miR-744-5p were predicted by bioinformatics analysis, and the expression level of CCND1 in ccRCC cells was verified by qRT-PCR and Western blotting. The relationship between miR-744-5p and CCND1 was further validated by dual luciferase reporter assay, and the role of the miR-744-5p/CCND1 axis in ccRCC was explored by rescue experiments.
RESULTS: MiR-744-5p was significantly downregulated in ccRCC tissues and cell lines (all P < 0.05), and its overexpression inhibited the proliferation, migration, and invasion of ccRCC cells (all P < 0.05). Bioinformatics analysis and dual luciferase reporter assay showed that CCND1 was a downstream target of miR-744-5p. The results of rescue experiments showed that upregulation of CCND1 could partially reverse the inhibitory effect of miR-744-5p overexpression on ccRCC cell proliferation, migration, and invasion (all P < 0.05).
CONCLUSION: MiR-744-5p inhibits the malignant phenotype of ccRCC cells by targeting CCND1, and the miR-744-5p/CCND1 axis may be a novel target for diagnosis and treatment of ccRCC.

Entities:  

Keywords:  CCND1; clear-cell renal cell carcinoma; miR-744-5p

Mesh:

Substances:

Year:  2022        PMID: 35673915      PMCID: PMC9178640          DOI: 10.12122/j.issn.1673-4254.2022.05.12

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  30 in total

Review 1.  Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression.

Authors:  Y Hosokawa; A Arnold
Journal:  Genes Chromosomes Cancer       Date:  1998-05       Impact factor: 5.006

Review 2.  Toward the promise of microRNAs - Enhancing reproducibility and rigor in microRNA research.

Authors:  Kenneth W Witwer; Marc K Halushka
Journal:  RNA Biol       Date:  2016-09-19       Impact factor: 4.652

Review 3.  Utility of Cyclin D1 in the Diagnostic Workup of Hematopoietic Neoplasms: What Can Cyclin D1 Do for Us?

Authors:  Wei Wang; L Jeffrey Medeiros
Journal:  Adv Anat Pathol       Date:  2019-09       Impact factor: 3.875

Review 4.  Role of miRNAs in tumor and endothelial cell interactions during tumor progression.

Authors:  Francesca Orso; Lorena Quirico; Daniela Dettori; Roberto Coppo; Federico Virga; Livia C Ferreira; Camilla Paoletti; Désirée Baruffaldi; Elisa Penna; Daniela Taverna
Journal:  Semin Cancer Biol       Date:  2019-08-03       Impact factor: 15.707

Review 5.  Epidemiology of Renal Cell Carcinoma.

Authors:  Umberto Capitanio; Karim Bensalah; Axel Bex; Stephen A Boorjian; Freddie Bray; Jonathan Coleman; John L Gore; Maxine Sun; Christopher Wood; Paul Russo
Journal:  Eur Urol       Date:  2018-09-19       Impact factor: 20.096

6.  MiR-125b promotes migration and invasion by targeting the vitamin D receptor in renal cell carcinoma.

Authors:  Xiyuan He; Shangfan Liao; Dongming Lu; Fabiao Zhang; Yingming Sun; Yongyang Wu
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

7.  MicroRNA-744-5p inhibits glioblastoma malignancy by suppressing replication factor C subunit 2.

Authors:  Fei Fan; Dongxiao Yao; Pengfei Yan; Xiaobing Jiang; Jie Hu
Journal:  Oncol Lett       Date:  2021-06-15       Impact factor: 2.967

8.  MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells.

Authors:  Michael Kleemann; Helga Schneider; Kristian Unger; Philip Sander; E Marion Schneider; Pamela Fischer-Posovszky; René Handrick; Kerstin Otte
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

9.  Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies.

Authors:  Xinan Sheng; Jie Jin; Zhisong He; Yiran Huang; Aiping Zhou; Jinwan Wang; Xiubao Ren; Dingwei Ye; Xu Zhang; Shukui Qin; Fangjian Zhou; Binhui Wang; Jun Guo
Journal:  BMC Cancer       Date:  2020-03-14       Impact factor: 4.430

10.  Long non-coding RNA LINC01116 is activated by EGR1 and facilitates lung adenocarcinoma oncogenicity via targeting miR-744-5p/CDCA4 axis.

Authors:  Ping Ren; Liang Chang; Xiaodong Hong; Lei Xing; Hong Zhang
Journal:  Cancer Cell Int       Date:  2021-06-05       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.